FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 300 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR ΚΑΡΚΙΝΟΣ ΠΑΓΚΡΕΑΤΟΣ November 22, 2018 FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes July 14, 2020 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and... May 12, 2022 Load more HOT NEWS 10 Ways to Provide Support During Breast Cancer Awareness Month Cannabis, cannabinoids and cancer – the evidence so far Mom Discovers She Has Breast Cancer After Weaning Twin Boys, Says... Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown
